Assessing HER2 amplification in breast cancer: findings from the Australian In Situ Hybridization Program

In August 2006, the Australian government approved subsidized trastuzumab therapy for human epidermal growth factor receptor 2 (HER2)-positive early breast cancer, and it was mandated that HER2 testing should be performed using in situ hybridization (ISH) rather than immunohistochemistry (IHC). Here...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Bilous, Michael, Morey, Adrienne L., Armes, Jane E., Bell, Richard, Button, Peter H., Cummings, Margaret C., Fox, Stephen B., Francis, Glenn D., Waite, Brigid, McCue, Glenda, Raymond, Wendy A., Robbins, Peter D., Farshid, Gelareh
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Springer US 2012
Aiheet:
Preclinical Study
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC3401497/
https://ncbi.nlm.nih.gov/pubmed/22678156
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-012-2093-6
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia